Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-12-22
2008-10-07
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S042000, C514S045000, C514S049000, C514S263100, C514S269000, C536S027100, C536S028100, C534S767000, C544S264000
Reexamination Certificate
active
07432272
ABSTRACT:
The application relates to 4′-substituted nucleoside derivatives of Formula I:wherein B and R1have any of the values described in the application, as well as to compositions comprising such compounds, to methods and intermediates useful for preparing such compounds, and to therapeutic methods comprising administering such compounds to animals in need thereof.
REFERENCES:
patent: 5413996 (1995-05-01), Bodor
patent: 5493030 (1996-02-01), Morgans et al.
patent: 5585397 (1996-12-01), Tung et al.
patent: 5633279 (1997-05-01), Morgans et al.
patent: 5654286 (1997-08-01), Hostetler
patent: 5670497 (1997-09-01), Bold et al.
patent: 5747498 (1998-05-01), Schnur et al.
patent: 5750343 (1998-05-01), Maag et al.
patent: 5750493 (1998-05-01), Schinazi et al.
patent: 5811422 (1998-09-01), Lam et al.
patent: 5874577 (1999-02-01), Chen et al.
patent: 5914332 (1999-06-01), Chen et al.
patent: 6072053 (2000-06-01), Vince et al.
patent: 6174888 (2001-01-01), McQuire et al.
patent: 6312662 (2001-11-01), Robinson et al.
patent: 6319946 (2001-11-01), Hale et al.
patent: 6395763 (2002-05-01), Stamos et al.
patent: 6608027 (2003-08-01), Tsantrizos et al.
patent: 6767900 (2004-07-01), Ubasawa et al.
patent: 2001/0031773 (2001-10-01), Camden
patent: 2002/0119443 (2002-08-01), Becker et al.
patent: 2003/0109498 (2003-06-01), Yuasa et al.
patent: 2004/0121316 (2004-06-01), Birkus et al.
patent: 2004/0167096 (2004-08-01), Cheng et al.
patent: 0 267 050 (1988-05-01), None
patent: 0 441 192 (1991-01-01), None
patent: 0 465 297 (1992-01-01), None
patent: 0 531 597 (1993-03-01), None
patent: 0 632 048 (1995-01-01), None
patent: 0 786 455 (1997-07-01), None
patent: 0 852 233 (1998-07-01), None
patent: 0 919 562 (1999-06-01), None
patent: 1 295 879 (2003-03-01), None
patent: WO 88/06158 (1988-08-01), None
patent: WO91/19721 (1991-12-01), None
patent: WO 92/00988 (1992-01-01), None
patent: WO 92/18520 (1992-10-01), None
patent: WO 93/12123 (1993-06-01), None
patent: WO 93/24510 (1993-12-01), None
patent: WO 96/14314 (1996-05-01), None
patent: WO 96/40156 (1996-12-01), None
patent: WO 97/01558 (1997-01-01), None
patent: WO 98/04569 (1998-02-01), None
patent: WO 98/11906 (1998-03-01), None
patent: WO 98/15563 (1998-04-01), None
patent: WO 99/33815 (1999-07-01), None
patent: WO 99/62921 (1999-12-01), None
patent: WO 00/04033 (2000-01-01), None
patent: WO 00/52015 (2000-09-01), None
patent: WO 00/52015 (2001-02-01), None
patent: WO 01/13957 (2001-03-01), None
patent: WO 01/17982 (2001-03-01), None
patent: WO 01/19320 (2001-03-01), None
patent: WO 01/39724 (2001-06-01), None
patent: WO 01/46204 (2001-06-01), None
patent: WO 01/64693 (2001-09-01), None
patent: WO 01/39724 (2001-10-01), None
patent: WO 01/96329 (2001-12-01), None
patent: WO 01/96354 (2001-12-01), None
patent: WO 02/03997 (2002-01-01), None
patent: WO 02/06292 (2002-01-01), None
patent: WO 02/08241 (2002-01-01), None
patent: WO 02/14344 (2002-02-01), None
patent: WO 02/48165 (2002-06-01), None
patent: WO 02/057425 (2002-07-01), None
patent: WO 02/100415 (2002-12-01), None
patent: WO 02/103008 (2002-12-01), None
patent: WO 03/028737 (2003-04-01), None
patent: WO 02/48165 (2003-05-01), None
patent: WO 03/050129 (2003-06-01), None
patent: WO 03/059255 (2003-07-01), None
patent: WO 03/064383 (2003-08-01), None
patent: WO 03/066005 (2003-08-01), None
patent: WO 03/080078 (2003-10-01), None
patent: WO 02/103008 (2003-11-01), None
patent: WO 03/090690 (2003-11-01), None
patent: WO 2004/096234 (2004-11-01), None
patent: WO 2004/096818 (2004-11-01), None
patent: WO 2005/011709 (2005-02-01), None
patent: WO 2005/011709 (2005-02-01), None
patent: WO 2004/096818 (2005-04-01), None
Kato et al., “Enantio- and Diastereoselective Synthesis of 4′alpha-substituted Carbocyclic Nucleosides”, Tetrahedron: Asymmetry, 9 (1998), 911-914.
Maag et al., Synthesis and Anti-HIV activity of 4′-Azido and 4′-Methoxynucleosides, Journal of medicinal Chemistry, 1992, 35, 1440-1451.
Allen, Lee F. et al., CI-1040. (PDI84352), a Targeted Signal Transduction Inhibitor of MEK (MAPKK),Seminars in Oncology, Oct. 2003, pp. 105-116, vol. 30, No. 5, Elsevier Inc.
Bantia, Shanta et al., Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)—a novel potent and orally active immunosuppressive agent,International Immunopharmacology, 2001, pp. 1199-1210, Elsevier Science B.V.
Beauchamp, Lilia M., et al., Guanine, Pyrazolo[3,4-d]pyrimidine, and Triazolo[4,5-d]pyrimidine(8-Azaguanine) Phosphonate Acyclic Derivatives as Inhibitors of Purine Nucleoside Phosphorylase,Journal of Medicinal Chemistry, 1996, pp. 949-956, American Chemical Society.
Bohani D. W. et al., A-420983: a potent, orally active inhibitor of Ick with efficacy in a model of transplant rejection,Bioorganic&Medicinal Chemistry Letters, 2004, vol. 14.
Bzowska, Agnieszka et al., Purine nucleoside phosphorylases: properties, functions, and clinical aspects,Pharmacology&Therapeutics, 2000, pp. 349-425, vol. 88, Elsevier Science Inc.
Chapman, H. et al., Practical Synthesis, Separation, and Stereochemical Assignment of the PMPA Pro-Drug GS-7340, Nucleosides, Nucleotides & Nucleic Acids, 2001, pp. 621-628, vol. 20, Nos. 4-7, Marcel Dekker, Inc.
Conklyn, Maryrose et al., The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing,Journal of Leukocyte Biology, Dec. 2004, pp. 1-8, vol. 76, The Society for Leukocyte Biology.
De Clereq, E., Highlights in the Development of New Antiviral Agents,Mini Reviews in Medicinal Chemistry, 2002, 163-175, vol. 2, No. 2., Bentham Science Publishers, Ltd.
Evans, Gary B., Exploring Structure—Activity Relationships of Transition State Analogues of Human Purine Nucleoside Phosporylase,J. Med. Chem., 2003, 3412-3423, vol. 46, No. 15, American Chemical Society.
Gumina, Giuseppe et al., Advances in antiviral agents for hepatitis B virus,Antiviral Chemistry&Chemotherapy, 2001, 93-112, vol. 12, Suppl. 1, International Medical Press.
Gobec, S. et al., Phosphonate inhibitors of antiget 85C, a crucial enzyme involved in the biosynthesis of the mycobacterium tuberculosis cell wall,Bioorganic and Medicinal Chemistry Letters, 2004, vol. 14.
Hegedus, Louis S. et al., Synthesis of 4′-Methyl and 4′-cyano Carbocyclic 2′, 3′-Didehydro Nucleoside Analogues via 1,4-Addition to Substituted Cyclopentenones,J. Org. Chem., 2004, 8492-8495, vol. 69, No. 24, American Chemical Society.
Herczegh P., et al., Osteoadsorptive biosphosphonate derivatives of fluoroquinolone antibacterials,J. Med. Chem., 2002, vol. 45.
Hirabayashi, Hideki et al., Bone-Specific Drug Delivery Systems,Clinical Pharacokinetics, 2003, 1319-1330, vol. 42, No. 15.
Holy A. et al., Synthesis,Cllect. Czech. Chem. Commun., 1989, vol. 54, pp. 2190-2210.
Jain, Jugnu et al., Characterization of Pharmacological Efficacy of VX-148, a New, Potent Immunosuppressive Inosine 5′-Monophosphate Dehydrogenase Inhibitor,Journal of Pharmacology and Experimental Therapeutics, 2002, 1272-1277, vol. 302, No. 3, The American Society for Pharmacology and Experimental Therapeutics.
Karpenko, Inna L. et al., Synthesis and Antitherpetic Activity of Acyclovir Phosphonates, Nucleosides, Nucleotides & Nucleic Acids, 2003, 319-328, vol. 22, No. 3, Marcel Dekker, Inc.
Kato, Keisuke et al., Stereoselective synthesis of 4′-.alpha.-alkyclcarbovir derivatives based on an asymmetrical synthesis or chemo-enzymatic procedure,Chemical&Pharmaceutical Bulletin, 1999, 1256-1264, vol. 49, No. 9, Pharmaceutical Society of Japan.
Kato, Keisuke et al., Enantio- and diastereoselective synthesis of 4′-α-substituted carbocyclic nucleosides, Tetrahedron:Asymmetry, 1998, 911-914, vol. 9, Elsevier Science Ltd.
Kilpatrick, J. Michael, Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor, In vivo effects on blood 2′-deoxyguanosine in primates,International Immunopharmacology, 2003, 541-548, vol. 3, Elsevier Science B.V.
Kim, Choung
Fardis Maria
Kim Choung U.
Gilead Sciences, Inc.
Jiang Shaojia Anna
McIntosh, III Traviss C
Viksinins, Harris & Padys PLLP
LandOfFree
Antiviral analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antiviral analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antiviral analogs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4001287